Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

18 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Allergan Inc names Jim Hindman chief financial officer
Monday, 18 Aug 2014 09:00am EDT 

Allergan Inc:Says Jim Hindman has been named Executive Vice President, Finance and Business Development, Chief Financial Officer, effective immediately.Hindman succeeds Jeff Edwards, who has decided to step down from the position due to family commitment.  Full Article

Valeant Pharmaceuticals International Inc offer to acquire Allergan
Friday, 15 Aug 2014 05:00pm EDT 

Valeant Pharmaceuticals International Inc:Announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan Inc to Dec. 31.  Full Article

Allergan Inc files lawsuit in Federal Court against Valeant and Pershing Square
Friday, 1 Aug 2014 11:30am EDT 

Allergan Inc:Files lawsuit in the United States District Court for the Central District of California against Valeant Pharmaceuticals International, Inc. (Valeant), Pershing Square Capital Management, L.P. (Pershing Square) and principal, William A. Ackman.Alleges that Valeant, Pershing Square and Ackman violated federal securities laws prohibiting insider trading, engaged in other fraudulent practices, and failed to disclose legally required information.  Full Article

Allergan announces OZURDEX receives european positive opinion for the treatment of Diabetic Macular Edema
Friday, 25 Jul 2014 07:55am EDT 

Allergan Inc:Says the European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ) (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.CHMP is the scientific committee of the European Medicines Agency (EMA) that recommends medicines for Marketing Authorization across the 28 member states of the European Union.  Full Article

Allergan Inc raises FY 2014 outlook; gives FY 2015, 2016 EPS outlook above analysts' estimates; gives Q3 2014 outlook in line with analysts' estimates; gives charge outlook
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Sees FY 2014 EPS between $5.74 and $5.80.Sees FY 2015 EPS between $8.20 and $8.40.Sees FY 2016 EPS at about $10.00.Expects to incur total non-recurring pre-tax charges of between $375 and $425 million in connection with the restructuring and other costs.Sees FY 2014 total product net sales between $6.90 and $7.05 bln excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 total product net sales between $1.675 and $1.750 bln, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 non-GAAP diluted earnings per share between $1.44 and $1.47.FY 2014 EPS $5.70 and revenue of $6.98 bln - Thomson Reuters I/B/E/S.FY 2015 EPS $6.85 - Thomson Reuters I/B/E/S.FY 2016 EPS $8.14 - Thomson Reuters I/B/E/S.Q3 2014 EPS $1.45 and revenue of $1.72 bln - Thomson Reuters I/B/E/S.  Full Article

Allergan declares second quarter dividend
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Declares second quarter dividend of $0.05 per share.Payable on Sept. 5 to stockholders of record on Aug. 15.  Full Article

Allergan Inc announces U.S. FDA approval
Monday, 30 Jun 2014 08:10am EDT 

Allergan Inc:Receives approval from U.S. Food and Drug Administration (FDA) for OZURDEX(reg)(dexamethasone intravitreal implant) 0.7 mg as treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic).  Full Article

Valeant Pharmaceuticals International Inc commences exchange offer for Allergan Inc
Wednesday, 18 Jun 2014 09:30am EDT 

Allergan Inc:Says Valeant Pharmaceuticals International Inc announced that it has commenced an exchange offer for common stock of Allergan Inc.Under terms of offer, Allergan stockholders would be able to elect to exchange each of their Allergan shares for $72.00 in cash and 0.83 Valeant common shares, or an amount of cash, or number of Valeant common shares, in each case subject to proration.Valeant says amount of all cash and all stock elections would be determined prior to expiration of exchange offer.Offer is scheduled to expire at New York City time, on Aug. 15, 2014, unless offer is extended.Valeant expects to complete second-step merger promptly following consummation of exchange offer in order to acquire the remaining Allergan shares.  Full Article

Pershing Square Files lawsuit against Allergan Inc
Friday, 13 Jun 2014 06:00am EDT 

Allergan Inc:Pershing Square Capital Management, L.P. announced that an affiliate has filed a lawsuit in the Delaware Court of Chancery.Says it is seeking a declaratory judgment confirming that its actions in connection with the solicitation and receipt of revocable proxies to call a special meeting of shareholders of Allergan Inc.  Full Article

Valeant Pharmaceuticals International responds to Allergan 's rejection of merger proposal
Tuesday, 13 May 2014 08:01am EDT 

Valeant Pharmaceuticals International Inc:Says that it has responded to Allergan Inc.'s rejection of Valeant's proposal to combine with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share.Receives Allergan's letter rejecting Valeant's offer on May 12.  Full Article


Ackman's Pershing Square sees big payoff from Allergan deal

BOSTON - Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

Search Stocks